NASDAQ:FULC Fulcrum Therapeutics Q2 2025 Earnings Report $3.83 -0.02 (-0.52%) As of 08/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Fulcrum Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.29Beat/MissBeat by +$0.01One Year Ago EPSN/AFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFulcrum Therapeutics Announcement DetailsQuarterQ2 2025Date7/29/2025TimeBefore Market OpensConference Call DateTuesday, July 29, 2025Conference Call Time4:00PM ETUpcoming EarningsFulcrum Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 28, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fulcrum Therapeutics Earnings HeadlinesHalper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their ShareholdersAugust 19, 2026 | globenewswire.comFulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULCAugust 19, 2026 | businesswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 23 at 1:00 AM | Porter & Company (Ad)Fulcrum and Slate Medicines sign merger agreementAugust 18, 2026 | msn.comFulcrum Therapeutics to Become Slate Medicines in All-Stock MergerAugust 18, 2026 | marketwatch.comFulcrum Therapeutics Sees Unusually High Options Volume (NASDAQ:FULC)August 18, 2026 | americanbankingnews.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms. Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression. The company’s pipeline combines discovery-stage projects with clinical-stage assets, reflecting its commitment to translating foundational science into potential therapies for underserved genetic disorders. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum maintains research and development facilities in both Cambridge and the San Francisco Bay Area. The company is led by President and Chief Executive Officer Steven L. Holtzman, whose leadership team includes professionals with extensive experience in drug development, regulatory affairs and commercial strategy. Fulcrum collaborates with patient advocacy groups, academic institutions and contract research organizations to advance its programs and broaden access to promising new treatments. Fulcrum Therapeutics serves a global patient population by pursuing therapies for rare and serious genetic diseases with significant unmet medical need. The company’s integrated approach—combining a deep understanding of epigenetic mechanisms with state-of-the-art drug discovery capabilities—positions it to address complex disorders for which conventional therapeutic strategies have been largely ineffective.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/17 - 08/21Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t OverRoss Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss3 Stocks Came Roaring Back—Now They’re Flashing Warning SignsMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
